Daniela Kramer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniela Kramer has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anja Schmitt
University Hospital Münster, Department of Medicine A, Department of Hematology, Oncology and Pneumology, Münster, Germany
2 shared publications - Paula Grondona
Interfaculty Institute for Biochemistry, Eberhard Karls University of Tübingen, Tübingen, Germany
2 shared publications - Philip Bucher
University of Tübingen
2 shared publications - Stephan Hailfinger
Department of Medicine A, Münster University Hospital, Münster, GERMANY
2 shared publications - André Hennig
Center for Bioinformatics, Eberhard Karls University of Tübingen, Tübingen, Germany
1 shared publication - Anne Müller
Interfaculty Institute for Biochemistry, Eberhard Karls University of Tübingen, Tübingen, Germany
1 shared publication
Latest Publications
- 1 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (9) , 1805-1814.e6
Threonine Phosphorylation of IκBζ Mediates Inhibition of Selective Proinflammatory Target Genes
- 1 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (9) , 1805-1814.e6
Threonine Phosphorylation of IκBζ Mediates Inhibition of Selective Proinflammatory Target Genes
- 9 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (2) , 121-132
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.
- 9 January 2020
- Published by American Society of Hematology in Blood
- Vol. 135 (2) , 121-132
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.